Metabolic complications with the use of mTOR inhibitors for cancer therapy

BACKGROUND: mTOR inhibitors are now approved by regulatory agencies for the treatment of a variety of malignancies. The risk of metabolic complications with these agents is not well characterized. METHODS: PubMed was searched for articles published from 2001 until 2011. Eligible studies included pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Treat Rev
Hauptverfasser: Sivendran, Shanthi, Agarwal, Neeraj, Gartrell, Benjamin, Ying, Jian, Boucher, Kenneth M., Choueiri, Toni K., Sonpavde, Guru, Oh, William K., Galsky, Matthew D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4744486/
https://ncbi.nlm.nih.gov/pubmed/23684373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2013.04.005
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge